Nautilus Biotechnology (NAUT) Projected to Post Quarterly Earnings on Thursday

Nautilus Biotechnology (NASDAQ:NAUTGet Free Report) is expected to announce its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Nautilus Biotechnology Stock Down 2.3 %

Shares of NAUT stock opened at $1.67 on Thursday. Nautilus Biotechnology has a fifty-two week low of $1.56 and a fifty-two week high of $3.09. The stock has a market cap of $209.69 million, a P/E ratio of -2.98 and a beta of 1.21. The business has a fifty day simple moving average of $1.79 and a 200-day simple moving average of $2.29.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Nautilus Biotechnology stock. Bank of America Corp DE boosted its holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUTFree Report) by 37.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 49,419 shares of the company’s stock after buying an additional 13,363 shares during the period. Bank of America Corp DE’s holdings in Nautilus Biotechnology were worth $83,000 at the end of the most recent reporting period. 50.71% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group cut Nautilus Biotechnology from a “neutral” rating to a “sell” rating and dropped their price target for the company from $2.25 to $1.75 in a research report on Thursday, December 5th.

Get Our Latest Stock Analysis on NAUT

About Nautilus Biotechnology

(Get Free Report)

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

Read More

Earnings History for Nautilus Biotechnology (NASDAQ:NAUT)

Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.